Skip to content
ppharmaranks
Menu
Class IIOngoing

IMAAVY (nipocalimab-aahu) Injection recall

FDA recall D-0016-2027 · initiated Sep 23, 2026

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Oct 14, 2026How we research

J&J INNOVATIVE MEDICINE recalled IMAAVY (nipocalimab-aahu) Injection in Sep 2026 — an FDA Class II recall (D-0016-2027) because Presence of particulate matter.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Presence of particulate matter.

Something got into the product

A physical or chemical contaminant was found — glass or metal fragments, or a solvent that should not be there.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot JNYJ1208; Exp. 10/30/2027

Quantity recalled: 49 vials

Details

Product
IMAAVY (nipocalimab-aahu) Injection, 300 mg /1.62 mL (185 mg/mL) per single-dose vial, For Intravenous Infusion After Dilution, Rx only, Manufactured by: Janssen Biotech, Inc., Horsham, PA 19044. NDC: 57894-800-01
Recalling company
J&J INNOVATIVE MEDICINE
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
OH
Initiated
Sep 23, 2026
FDA report date
Oct 14, 2026

This recall is linked to a product we cover: Imaavy →

What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was IMAAVY (nipocalimab-aahu) Injection recalled?
J&J INNOVATIVE MEDICINE recalled IMAAVY (nipocalimab-aahu) Injection in Sep 2026 — an FDA Class II recall (D-0016-2027) because Presence of particulate matter. May cause temporary or medically reversible harm; low probability of serious harm.
Why was IMAAVY (nipocalimab-aahu) Injection recalled?
Per the FDA enforcement record, the reason for recall D-0016-2027 was: Presence of particulate matter.
Is a recalled IMAAVY (nipocalimab-aahu) Injection dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of IMAAVY (nipocalimab-aahu) Injection are affected?
Distributed: OH. The recall covers these lots — Lot JNYJ1208; Exp. 10/30/2027. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0016-2027.

Source: openFDA Drug Enforcement record D-0016-2027 ↗

← All drug recalls